Medicapedia ESENCA
Image of Sarcopenia
Image: Wikimedia Commons

Sarcopenia

1989 · geriatric term for age-related muscle loss

Share:FacebookWhatsApp

For centuries, the loss of muscle that comes with age was seen as an ordinary part of getting older, rarely given a name of its own. Sarcopenia, from the Greek sarx, meaning flesh, and penia, meaning poverty or shortage, literally describes a shortage of muscle. Irwin Rosenberg introduced the term in 1989 to describe the gradual decline of skeletal muscle mass, the tissue attached to bones that powers movement.

Before that, muscle loss in older people was usually attributed in a vague way to age, inactivity or general weakness, with no diagnostic category of its own. Naming the condition made it possible to study it as a separate entity. Today it is understood that sarcopenia affects not only mass but also strength and muscular performance, and that it is linked to a poorer quality of life, falls, disability and fractures. It is also associated with osteoporosis, another factor that shapes longevity in later life.

It should be distinguished from cachexia, a wasting of muscle seen in diseases such as cancer, which is driven by inflammatory proteins called cytokines. Specialists divide sarcopenia into primary, which accompanies ageing, and secondary, which arises from an underlying illness or from a medication. As for its causes, a study in mice led by Andrew R. Marks at the Columbia University Medical Center, in the United States, suggested that calcium loss in certain proteins of muscle cells limits the ability of muscle fibres to contract, with ryanodine receptors involved. This is an experimental finding and does not explain every case on its own.

Diagnosis has long been difficult. There is no absolute level of muscle loss that serves as a reference, and no clinical test accepted by everyone. Researchers use tools such as dual-energy X-ray absorptiometry (DEXA), computed tomography and calf measurement. Baumgartner and colleagues proposed defining sarcopenia as muscle mass two standard deviations below the average of healthy young adults. In 2010 the European Working Group on Sarcopenia in Older People (EWGSOP) published the first clinical definition, updated in 2019. It distinguishes probable sarcopenia, when strength is reduced; confirmed sarcopenia, when muscle quantity or quality is also shown to be lower; and severe sarcopenia, when physical condition is affected.

Over time, sarcopenia has moved from a descriptive idea to a recognised condition. In 2016 it received its own code in the International Classification of Diseases (ICD-10), which places it among disease states and encourages research. Even so, debate about its criteria continues, and researchers are still looking for biological markers and simpler screening tools that could detect it before it causes disability.

Key dates

  • 1989 Irwin Rosenberg introduces the term sarcopenia to describe muscle loss in ageing.
  • 2010 The EWGSOP publishes the first clinical definition of sarcopenia.
  • 2016 The condition is given its own code in the International Classification of Diseases.
  • 2019 The EWGSOP updates its clinical definition.

Key figures: Irwin Rosenberg

Curiosities and anecdotes

A name with Greek roots

The term combines sarx, meaning flesh, and penia, meaning shortage. Its literal meaning captures the idea of losing muscle tissue.

Legs do not age equally

According to the studies cited, the muscles of the lower leg are less affected by ageing than those of the upper leg, both in people and in mice.

No single test

To date there is no clinical test accepted by everyone for diagnosing sarcopenia, and the criteria for defining it are still debated among expert groups.

Sources

Original Medicapedia text based on:

Last updated: 5 November 2026 · How Medicapedia is made

A project by Alejandro Rosàs Navarro, family physician and specialist in preventive medicine and public health. Spotted a mistake? Write to info@medicapedia.org.